Clinical Characteristics and Treatment of MOG-IgG–Associated Optic Neuritis

[1] Schluesener HJ(1987)A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease J Immunol 139 4016-4021

[2] Sobel RA(2006)How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis Ann Neurol 60 12-21

[3] Linington C(2003)Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event N Engl J Med 349 139-145

[4] Weiner HL(2018)MOG encephalomyelitis: international recommendations on diagnosis and antibody testing J Neuroinflamm 15 134-3138

[5] Steinman L(2018)Defining distinct features of anti-MOG antibody associated central nervous system demyelination Ther Adv Neurol Disord 11 1756286418762083-15

[6] Zamvil SS(2017)Clinical presentation and prognosis in MOG-antibody disease: a UK study Brain 140 3128-423

[7] Berger T(2018)Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome Am J Ophthalmol 195 8-1360

[8] Rubner P(2019)Do Myelin Oligodendrocyte Glycoprotein Antibodies Represent a Distinct Syndrome? Journal of Neuro-Ophthalmology 39 416-137

[9] Schautzer F(2016)Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes J Neurol 263 1349-97

[10] Egg R(2016)MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome J Neuroinflammation 13 280-301

[1] Schluesener HJ(1987)A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease J Immunol 139 4016-4021

[2] Sobel RA(2006)How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis Ann Neurol 60 12-21

[3] Linington C(2003)Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event N Engl J Med 349 139-145

[4] Weiner HL(2018)MOG encephalomyelitis: international recommendations on diagnosis and antibody testing J Neuroinflamm 15 134-3138

[5] Steinman L(2018)Defining distinct features of anti-MOG antibody associated central nervous system demyelination Ther Adv Neurol Disord 11 1756286418762083-15

[6] Zamvil SS(2017)Clinical presentation and prognosis in MOG-antibody disease: a UK study Brain 140 3128-423

[7] Berger T(2018)Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome Am J Ophthalmol 195 8-1360

[8] Rubner P(2019)Do Myelin Oligodendrocyte Glycoprotein Antibodies Represent a Distinct Syndrome? Journal of Neuro-Ophthalmology 39 416-137

[9] Schautzer F(2016)Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes J Neurol 263 1349-97

[10] Egg R(2016)MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome J Neuroinflammation 13 280-301